• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

    295.85 -1.60 (-0.54%)
    Streaming Delayed Price Updated: 11:48 AM EDT, May 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 147,102
    Open 299.00
    Bid (Size) 295.62 (360)
    Ask (Size) 296.08 (40)
    Prev. Close 297.45
    Today's Range 295.11 - 301.09
    52wk Range 284.28 - 495.55
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alnylam Issues 2025 Corporate Responsibility Report
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build ↗
    Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing... 
    Via MarketBeat

    Performance

    YTD
    -26.1%
    -26.1%
    1 Month
    -4.1%
    -4.1%
    3 Month
    -10.2%
    -10.2%
    6 Month
    -31.9%
    -31.9%
    1 Year
    +2.0%
    +2.0%

    More News

    Read More
    News headline image
    New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam’s First Billion-Dollar Quarter Smashes Q1 Estimates, ALNY Surges ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Strong Growth Fundamentals Align with a High-Probability Technical Setup ↗
    Via Chartmill
    News headline image
    Alnylam to Webcast Presentations at Upcoming Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam (ALNY) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Emerges as a Top GARP Stock Pick ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point ↗
    Via Chartmill
    Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Case Study in Affordable Growth ↗
    Via Chartmill
    News headline image
    Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    Via Investor Brand Network
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    Via MarketMinute
    News headline image
    Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast TTR Investor Webinar
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally ↗
    Via Stocktwits
    News headline image
    Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property

    Frequently Asked Questions

    Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
    Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
    What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 295.85
    When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 05/26/26 11:48 AM ET
    What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 35.16B
    How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
    Alnylam Pharmaceuticals, Inc. - Common Stock has 35B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.